TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05650385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1962
Description: B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
Study: NCT05592717

Intervention type: DRUG
Intervention: Yutiq
Description: YUTIQ® 0.18 mg as an intravitreal injection in the designated study eye.
Study: NCT05669911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teal Health Self-Collection Device Group
Description: Participants will use the Instructions for Use to perform self-collection of cervicovaginal cells using the Teal Health Self-Collection Device, and will fill out a usability survey and a satisfaction and needs survey. A Pap smear will be performed by a clinician before or after self-collection.
Study: NCT06229275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pap smear collection using the Personal Pap Smear (PPS) Device
Description: Diagnostic Test: Use of PPS device to collect cervical cells during pap smear collection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Pap smear collection using the Rovers Cervex-Brush
Description: Diagnostic Test: Use of Rovers Cervex-Brush to collect cervical cells during pap smear collection.
Study: NCT06405724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 133mg LB 20mL thoracic paravertebral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% ropivacaine 20mL thoracic paravertebral nerve block
Study: NCT05597488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS guided portal pressure gradient measurement
Description: EUS-guided PPGM is performed under monitored anaesthesia. The linear array echoendoscope is passed from the mouth into the stomach and duodenum, as with a standard exam. Under endoscopic ultrasound guidance, a 25 gauge EUS needle (Echotip, Cook Medical, USA) primed with heparin 100 USP/ml is then placed across the stomach or duodenal wall and through the liver parenchyma into the portal vein (Figure 3). A pressure measurement is then obtained from the compact pressure transducer attached to the handle of the needle (Figure 4). Three separate measurements are made with re-priming of heparin (less than 0.5 ml). The needle is then removed from the portal vein and liver, if necessary. The process is repeated for the hepatic vein (Figure 5). The EUS - PPG is calculated by subtracting the average of the three hepatic vein pressure measurements from the average of the 3 direct portal vein pressure measurements.
Study: NCT05887388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect-Home Plus
Description: Connect-Home Plus will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Plus Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home Plus care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses,therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the illness and functional needs. In Step 2, a dementia caregiving specialist will call the patient's home three times within 30 days of discharge. Both intervention steps will focus on key care needs, such as 1) home safety; 2) care of symptoms of ADRD; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
Study: NCT05612620

Intervention type: DIAGNOSTIC_TEST
Intervention: coulture
Description: Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.

Intervention type: DIAGNOSTIC_TEST
Intervention: coulture
Description: Samples from the vagina, fornix and cervical canal will be taken by introducing a flocked nylon swab to the vagina via a speculum and circular swabbing for 5-10 seconds before using any antiseptics.
Study: NCT06214065

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI will be performed pre- and post-rTMS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI
Description: fMRI will be performed pre- and post-rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: TMS procedures are scheduled during study sessions 2-4 between the two MRI scans on those days. Because rTMS induces neural changes that last about 1 hour, rTMS will be applied immediately before the second MRI scan on each day. Prior to the TMS visits, target coordinates and orientation vectors will be generated from the MRI data and the e-field models and loaded into Localite along with the participant's reconstructed T1 image. During the visits, the participant's head will be co-registered to the T1 using fiducial points at the Nasion and Tragi. TMS pulses will be delivered, using the Localite software to target and track the optimal orientation calculated with e-field modeling.
Study: NCT04291898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMPLATZER™ Septal Occluder.
Description: Implantation of the AMPLATZER™ Septal Occluder in the ASD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlutech Figulla Flex II®
Description: Implantation of the Occlutech Figulla Flex II® in the ASD.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GORE® CARDIOFORM ASD Occluder
Description: Implantation of the GORE® CARDIOFORM ASD Occluder or GORE® CARDIOFORM Septal Occluder in the ASD.
Study: NCT05169489

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bbT369
Description: bbT369 is a genetically modified autologous T cell immunotherapy product consisting of T cells that are transduced with a single lentiviral vector (LVV) to express anti-CD79a and anti-CD20 chimeric antigen receptors (CARs) and transfected with an mRNA encoding the CBLB-targeting megaTAL enzyme to edit the CBLB gene, suspended in a cryopreservative solution.
Study: NCT04413461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous Electro Neuro Stimulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TENS Sham
Description: placebo of Transcutaneous Electro Neuro Stimulation : similar device without electro stimulation
Study: NCT05028543

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional TLH
Description: Procedure: conventional Total laparoscopic hysterectomy the uterine artery will be identified close to the isthmus then coagulated at this level, close to the uterus , using bipolar diathermy. The utero-vesical fold will be dissected and the bladder will be pushed down done.. The vasculature of the uterus will now secured and this will be evidenced by the pale color of the fundus.~Using either bipolar diathermy , the cornual pedicles on one side will be desiccated and cut. Also, both the uterosacral and cardinal ligaments will be coagulated and cut. So that, the opposite side pedicles can be taken care of.. The infundibulopelvic ligaments will be coagulatd and cut if it is necessary to remove both ovaries. A vaginal cuff was inserted into the vagina to identify the vault, which will then cut laparoscopically using a monopolar hook, where the specimen will be completely detached.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clipping of utrine artery at its origin before bginning of TLH
Description: the uterine artery will be dissected using posteriorly and medially to the infundibulopelvic ligament, the ureter should be first identified. The surgeon may grab the obliterated umbilical artery at the anterior abdominal wall and retract it. The movement of the umbilical artery may be Seen at the ovarian fossa perpendicular to the ureter~The uterine vessels will be clipped at their origin from the hypogastric vessels using aclip applier which will be introduced through 10mm trocar. clipping of the artery will be performed through application of two 5 mm size metallic clips in continuity and complete the laparoscopic hysterectomy with the same steps of the conventional method.
Study: NCT05345899

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Evaluation of vitamin C level in plasma
Description: A protocol-specific blood test wil assess the vitamin C level in plasma

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of quality of life
Description: Several questionnaire will be completed by patients to evaluate quality of life: Analog and visual scale (EVA) pain, Neuropathic pain (DN) 4 questionnaire, EVA fatigue, Short Form (SF) 12 questionnaire and Hospital Anxiety and Depression scale (HAD questionnaire)
Study: NCT05441748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: The intervention treatment will contain walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnut Oil
Description: The intervention treatment will contain walnut oil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control treatment will contain corn oil.
Study: NCT02658396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GO-203-2C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT06048978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercial native starch without processing
Description: A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Commercial native starch without processing
Description: A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified starch with extrusion processing
Description: A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified starch with extrusion processing
Description: A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
Study: NCT06384014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: retrograde and orthograde root canal filling
Description: Apical resection application after root canal filling

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: retrograde and orthograde root canal filling
Description: Apical resection application after root canal filling
Study: NCT05306535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal reduction
Description: Occlusal reduction of the experimental single rooted tooth after root canal completion will be done to evaluation reduction in postoperative pain and sensitivity to percussion
Study: NCT05288803

Intervention type: OTHER
Intervention: Clinical decision support tool (CDS tool)
Description: The investigators will integrate the CDS tool into clinical practice at each participating clinic after data collection for the Control cohort is complete. All physical therapists at the participating clinic locations will use the CDS tool to inform rehabilitation decision making for Veterans with total knee arthroplasty. The CDS tool will provide personalized information regarding each Veterans' recovery in addition to personalized visit utilization guidelines. Clinicians will use the CDS tool with Veterans at their initial postoperative visits and every 2weeks throughout their course of care thereafter.
Study: NCT05283941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pistachio Group
Description: Consumption of 2-ounce packs of pistachio nuts, daily, for 12 weeks.
Study: NCT05793268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nuc Discontinuation
Description: Eligible patients are randomly allocated with a 1:1 ratio to continue viral suppression or stop the treatment (entecavir or tenofovir). Patients will be followed up for 3 years. For patients who are assigned to the finite Nuc therapy, they should be monitored monthly for the initial 3 months and then every 3-6 months thereafter for relapse.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir or Tenofovir
Description: Continuation of either entecavir or tenofovir treatment for 3 years
Study: NCT05844007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Yoga
Description: Trauma-informed yoga intervention, delivered either in-person or remotely for 6 weeks, twice weekly for 45 minutes sessions
Study: NCT05484895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeTest-WeLink
Description: WeTest-WeLink application on the WeChat platform provides videos on HIV self-testing and linkage to care; informational articles on HIV, sexually transmitted infections (STI), testing, antiviral treatment (ART), and care; online behavioral self-assessments; linkage to providers; local data reports; stories about coping, wellness, and social support; two-way communication with NGO; and free, additional HST.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: Contact information of local NGO for emergency referrals; free additional HST.
Study: NCT01081106

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Low-Level Laser Therapy
Description: A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration.
Study: NCT06001957

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole exome sequencing
Description: Bioinformatic analysis of raw WES data and variants prioritization were performed as previously described.~Reads were aligned to the hg38 reference genome sequence and visualized by Integrative Genomic Viewer.
Study: NCT05198440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive neuromodulation
Description: The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalography
Description: The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anatomical MRI
Description: The modulations of the vection phenomenon will then be studied over two sessions of 1h30, separated by a minimum of 3 to a maximum of 15 days (the first session will be performed following the MRI). Each session will include: the installation of an EEG headset and the parameterization of the stimulation (30 min), then a phase of recording of the vection with neuromodulation (1h) according to 2 experimental conditions:~* Experiment 1: recording of vection at rest (20 min), then during and after neurostimulation by tES (20 min). Active and sham (placebo) stimulation will be tested separately during the two sessions (counterbalanced order).~* Experiment 2: recording of vection during neuromodulation by rTMS triggered in real time (1h). Triggering will be based on behavioral response (experiment 2a) or oscillatory activity detection (experiment 2b). Active and sham (placebo) stimulation will be tested in both sessions (randomized order).
Study: NCT05272501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calming Touch
Description: The calming treatment consists of deep pressure massage and gentle facilitation. The therapist works with the vertical axis, center, respiration, body boundaries and the feet.
Study: NCT05733117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: cholecalciferol
Study: NCT05029778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine 3g + L-Citruline 2 g
Description: receive L-arginine 3g + l-Citruline 2 g PO, for 24 h, until birth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: receive placebo 3g PO, for 24 h, until birth.
Study: NCT05965544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain (preoperative)
Description: After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain (Postoperative)
Description: After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
Study: NCT06628830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VamosJuntxs App
Description: Psychoeducational materials (videos, information and interactive exercises) about depression, anxiety and social support~Skills training through information and activities based on the principles of cognitive behavioral therapy (cognitive restructuring, behavioral activation, emotional regulation, problem solving and exposure)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Web Conciencia Saludable
Description: mental health psychoeducational campaign (https://concienciasaludable.uchile.cl/)